Supplementary Table 1. Additional exploratory endpoints in BUILDER-1 part 1 at week 12

Endpoint	**Placebo n=51**	**TCZ 8 mg/kg n=51**
ASAS 5/6, n (%)	8 (15.7)	13 (25.5)
ASAS partial remission, n (%)	1 (2.0)	0 (0)
ASAS–CRP status, mean (SD)	3.4 (0.96)	2.5 (0.86)

ASAS, Assessments in Ankylosing Spondylitis Response Criteria; CRP, C-reactive protein; SD, standard deviation.

Supplementary Table 2. Safety of TCZ in BUILDER-1 and BUILDER-2 (safety population)

	TCZ 8 mg/kg n=355	**Rate per 100 PY (95% CI)**
Total PY	169.94	
Top 5 ranked SOCs for all AEs and eye disorders SOC, n (patients with ≥1 AE)		
All AEs	352 (166)	207.1 (186.1-229.9)
Infection and infestations SOC	63 (56)	37.1 (28.5-47.4)
Gastrointestinal disorders SOC	48 (41)	28.2 (20.8-37.5)
Musculoskeletal and connective tissue disorders SOC	43 (34)	25.3 (18.3-34.1)
Investigations SOC	33 (25)	19.4 (13.4-27.3)
Skin and subcutaneous tissue disorders SOC	27 (24)	15.9 (10.5-23.1)
Eye disorders SOC (9th-ranked SOC)	14 (12)	8.2 (4.5-13.8)
Top 5 ranked SOCs for SAEs, n (patients with ≥1 SAE)		
SAEs	17 (17)	10.0 (5.8-16.0)
Immune system disorders SOC	5 (5)	2.9 (1.0-6.9)
Musculoskeletal and connective tissue disorders SOC	4 (4)	2.4 (0.6-6.0)
Gastrointestinal disorders SOC	2 (2)	1.2 (0.1-4.3)
Infections and infestations SOC	2 (2)	1.2 (0.1-4.3)
Eye disorders SOC	1 (1)	0.6 (0.0-3.3)

AE, adverse event; CI, confidence interval; PY, patient-year; SAE, serious adverse event; SOC, system organ class; TCZ, tocilizumab.